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ABSTRACT  
The  negative-regulatory  feedback-loop  between  p53  and  hdm2  forms  part  of  a  finely-
balanced regulatory-network of proteins that controls cell-cycle progression and commitment 
to apoptosis. Expression of hdm2, and its mouse orthologue mdm2, is known to be induced 
by p53, but recent evidence has demonstrated mdm2 expression can also be regulated via p53 
independent pathways. However the p53 independent mechanisms that control transcription 
of the human hdm2  gene have not been studied. Differential levels of  hdm2 mRNA and 
protein expression have been reported in several types of human malignancy, including breast 
cancers, in which hdm2 expression correlates with positive estrogen-receptor-α (ERα) status. 
Experimental  models  have  demonstrated  that  hdm2  over-expression  can  promote  breast 
cancer development. Here we show that the elevated level of hdm2 protein in ERα
+ve breast 
cancer cell lines such as MCF-7 and T47D is due to transcription from the p53 inducible P2 
promoter of hdm2. The P2 promoter is inactive in ERα
-ve cell lines such as SKBr3. Hdm2-P2 
promoter activity in T47D cells is independent of p53, as well as of known regulators of the 
mouse mdm2-P2 promoter, including ERα and ras-raf-MEK-MAPK signalling. We show that 
hdm2-P2  activity  in  T47D  cells  is  dependent  on  the  integrity  of  both  an  evolutionarily 
conserved AP1-ETS element and a non-conserved upstream (nnGGGGC)5 repeat sequence. 
Lack  of  hdm2-P2  activity  in  ERα
-ve    cells  is  shown  to  be  a  consequence  of  reduced 
transcriptional activation through the AP1-ETS element. Over-expression of ETS2 in SKBr3 
cells  reconstitutes  AP1-ETS  element-dependent  hdm2-P2  promoter  activity,  resulting  in 
increased levels of hdm2 protein in the cells. Our findings support the hypothesis that the 
elevated levels of hdm2 expression reported in cancers such as ERα
+ve breast tumors play an 
important  role  in  the  development  of  these  tumors.Regulation of hdm2 in breast cancer    Phelps et al 
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INTRODUCTION  
  Sporadic  human  breast  tumors  show  a  high  degree  of  genotypic  and  phenotypic 
diversity (1, 2). Despite this diversity, the sub-classification of tumors on the basis of their 
expression  of  the  steroid  hormone  receptor,  estrogen  receptor-α  (ERα)
3,  and  its 
transcriptional target, progesterone receptor, has proven to be a useful predictor of prognosis 
and therapeutic response (3). ERα is detectable in approximately two-thirds of breast cancers, 
and its expression correlates with a well-differentiated phenotype (4) and a dependence on 
the  mitogenic  action  of  estrogen  for  tumor  growth  (2).  Recent  gene  expression  profiling 
studies have clearly demonstrated that ERα status is associated with a distinct pattern of 
transcription of several hundred genes (5, 6). 
  In common with several other human tumor types (7), resistance to chemotherapy in 
breast cancer has been correlated with the presence of inactivating mutations in the p53 tumor 
suppressor gene (8, 9). This is consistent with the central role played by p53 in the stress-
induced up-regulation of transcription of genes that induce cell cycle arrest and apoptosis. 
(10). P53 gene mutation occurs in approximately 18 % of breast tumors according to a meta-
analysis of published reports (11), and shows a strong correlation with ERα
-ve tumor status (9, 
12). The frequency of p53 mutation in tumors expressing both ERα and progesterone receptor 
has been shown to be as low as 9% (12), which compares to an overall rate of 50-55% in all 
human cancers (13), indicating that the selection pressure for the acquisition of p53 mutation 
is relatively low in these breast tumors (14). Several lines of evidence now indicate that this 
reduced  selection  pressure  is  a  consequence  of  multiple  genotypic  and  phenotypic 
characteristics of these tumor cells. Firstly, it has been demonstrated that in a proportion of 
these cancers, the p53 protein is sequestered in the cytoplasm of the cell where it is unable to 
function as a transcription factor (15). Secondly, levels of transcription of p53 mRNA are low 
in some breast cancers due to reduced HOXA5 transcription factor activity (16). Furthermore, Regulation of hdm2 in breast cancer    Phelps et al 
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the  p53  dependent  apoptotic  response  is  reduced  in  some  breast  tumors  due  to  reduced 
expression of ASPP proteins (17). Finally, several reports have also demonstrated that the 
expression of hdm2, which is the major negative-regulator of p53 protein levels and activity 
in the cell (18-21), is up-regulated in ERα
+ve breast cancers at the protein and mRNA level 
(22-27). Mdm2 promotes breast cancer formation in murine models (28), and over-expression 
of hdm2 in human tumors such as sarcomas, in which the hdm2 gene is amplified (29), results 
in  a  reduced  rate  of  p53  mutation  in  these  cancers.  The  mechanism  of  increased  hdm2 
expression in ERα
+ve breast tumors is currently unknown and, because transcription of hdm2 
is itself up-regulated by p53 (30, 31), it is not known whether this increased expression is 
merely a consequence, rather than a cause, of the retention of wild-type p53 in these tumors.  
Hdm2 expression is regulated by transcription from two distinct promoters, P1 and P2 
(30). Transcription from P1 occurs at low levels in most cells, whereas P2 is highly induced 
by p53 due to the presence of evolutionarily conserved p53 response elements (p53-RE) in 
both the murine mdm2-P2 (32, 33) and human hdm2-P2 (30) promoters. Studies dissecting 
the  mechanisms  that  control  transcription  of  mdm2  and  hdm2  have  focussed  on  the  P2 
promoter, primarily because the human P1 promoter dependent transcript is poorly translated 
(34). With the exception of the study by Zauberman et al (30), which identified the p53-
responsive elements in the human hdm2-P2 promoter, mechanistic studies have to date been 
limited to the analysis of the murine P2 promoter. A number of functional, p53 independent 
response elements have been identified in this promoter, notably a thyroid hormone response 
element which is active in pituitary cells (35), and a combination of a 5’ ETS binding site and 
composite AP1-ETS site that is required for  activation of the promoter by  growth factor 
dependent  ras-raf-MEK-MAPK  signalling  pathways  (36,  37).  The  mechanism  whereby 
mdm2 expression can be regulated by other factors, most notably ERα in ras-transformed 
murine fibroblasts (38) has yet to be defined. It is important to note, however, that levels of Regulation of hdm2 in breast cancer    Phelps et al 
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murine P2 transcript in non-stressed adult tissues has been demonstrated to be essentially p53 
independent (39). 
In this paper we have investigated the mechanism underlying the increased levels of 
hdm2 expression in ERα
+ve breast tumor cells. We have demonstrated that both P1 and P2 
promoter derived mRNA transcripts are differentially expressed in a panel of breast cancer 
cell lines, and that the P2 promoter is activated by a p53 independent pathway in ERα
+ve  cell 
lines such as MCF-7 and T47D. T47D cells provide a useful experimental system to study the 
role of estrogens on the proteins involved in p53-dependent cell cycle control (40). We have 
therefore used these cells to dissect the transcription factor response elements in the human 
hdm2-P2  promoter  which  drive  hdm2  expression  in  ERα
+ve  cells,  and  have  subsequently 
identified a transcription factor which is able to restore hdm2-P2 promoter activity in ERα
-ve  
cells. 
 
MATERIALS AND METHODS  
Culture of human breast cancer cell lines. Breast cell lines were selected for this study 
based  on  a  previous  report  (23).  All  lines  were  cultured  in  Dulbecco’s  modified  Eagles 
medium  (Invitrogen)  supplemented  with  10%  fetal  calf  serum  (Autogen  Bioclear).  The 
following reagents, dissolved in dimethyl sulphoxide (DMSO), were added to the medium 
where  indicated:  ICI  182780  (Tocris),  U0126  (Promega),  and  PD98059  (Promega).  Cells 
were exposed to ionising radiation using a modified 225 kV X-ray unit (Gulmay Medical, 
UK) at a dose rate of 1.15 Gy/min. 
 
RNA analysis. Total RNA extraction was performed using RNAzol B (Biogenesis Inc.). For 
RT-PCR analysis of hdm2 transcripts 1 µg of RNA was reverse-transcribed in a 40 µl volume 
using  MMLV-reverse  transcriptase  (Promega)  and  O3  primer  5’-Regulation of hdm2 in breast cancer    Phelps et al 
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CTGCCTCGAGTCTCTTGTTCCGAAGCTGG-3’. 2 µl cDNA product was used as target in 
50 µl PCR reactions containing O1b/O3 or O2/O3 primer pairs for the amplification of hdm2-
P1    and  -P2  promoter  derived  transcripts  respectively  (O1b  5’-
CTGGGGAGTCTTGAGGGACC-3’,  O2  5’-CCTGTGTGTCGGAAAGATGG-3’).  PCR 
conditions were the same for both products (95°C 30 s, 58°C 30 s, 72 °C 1 min), except that 
cycle number was optimised to ensure that amplification was terminated in the exponential 
phase:  P1  transcript,  30  cycles;  P2  transcript,  25  cycles.  Products  were  of  the  predicted 
molecular  size,  and  were  verified  by  sub-cloning  into  pGEMTeasy  (Promega)  and 
sequencing. RT-PCRs using oligo dT and ß actin primers were used to control for levels of 
input  mRNA,  and  were  also  terminated  in  the  exponential  phase  of  PCR  (22  cycles). 
Ribonuclease  protection  assay  (RPA)  was  performed  according  to  the  manufacturers 
instructions (Ambion), using cloned O2/O3 PCR product as a probe. PCR and RPA results 
were quantified using a Kodak KDS1D imaging system. 
 
Protein  analysis.  Cells  were  washed  with  phosphate  buffered  saline,  pelleted  by 
centrifugation at 1000 g, snap frozen and stored at -80°C. For immunoblotting, pellets were 
lysed for 15 min at 4°C in denaturing urea buffer (7 M urea, 0.1 M dithiothreitol, 0.05% 
Triton X-100, 25 mM NaCl, 20 mM HEPES pH7.6) then clarified by centrifugation at 13000 
g for 10 min. Protein concentration was determined by the method of Bradford (Biorad). 
Immunoblotting was performed by standard procedures, as described previously (41) and 
membranes were probed for hdm2 using monoclonal antibody (mAb) 2A9 or 2A10 (42), p53 
(mAb  DO-1  or  DO-12,  Serotec)  or  ETS2  (Rabbit  polyclonal  C-20,  Santa  Cruz  Biotech). 
Equal protein loading was confirmed on all immunoblots using rabbit anti-actin antibody 
(Sigma). Bands were visualised by chemiluminescence (Supersignal, Pierce) and quantified 
using a Fluor-S MAX system (Biorad) .  Regulation of hdm2 in breast cancer    Phelps et al 
  7 
 
Plasmids, transfections and reporter gene assays. Genomic hdm2 sequence was amplified 
from  normal  human  liver  DNA  and  ligated  into  pGL3-Basic  using  the  MluI/XhoI  sites 
(Promega) to generate reporter construct hdm2luc01. The sequence of the inserted 895 b.p. 
region ((-602) to (+293) relative to the start of exon 2) was identical to that generated by the 
human genome project (AC026121.10) with the exception of two single base pair differences 
(C-470T, which is a documented polymorphism, and G-133A). Further constructs containing 
deletions of the hdm2 promoter (luc23, luc06, luc02 and luc03) (Fig. 4A) were generated by 
proof-reading PCR of hdm2luc01 using primers containing Mlu1 and Xho1 sites, followed by 
ligation into pGL3-Basic. Analysis of potential transcription factor binding sites in the hdm2-
P2  promoter  was  performed  using  MatInspector  (http://www.genomatix.de/cgi-
bin/matinspector/matinspector.pl). Mutations and deletions were introduced into hdm2luc01 
using  the  QuickChange  mutagenesis  kit  (Stratagene)  and  all  constructs  were  verified  by 
sequencing (MWG Biotech). Forward site-directed mutagenesis primers used are as follows 
(complementary reverse primers not shown):  
  ∆EBOX 5’-GGGGCATGGGGCAGGCTTTGCGGAGG-3’ (3 b.p. deletion),  
  ∆ETSb/c 5’-GCTTCGGCGCGGTGATCGCAGGTGCC-3’ (10 b.p. deletion), 
∆AP1 5’-GTGGGCAGGTACACTCAGCTTTTC-3’ (2 b.p. substitution), 
∆ETSa 5’-CTCAGCTTTAGCTCTTGAGCTGGTC-3’ (2 b.p. substitution).  
 
Other  vectors  used  in  this  study  have  been  described  previously; 
pCDNA3.1mychislacZ  for  β-galactosidase  (Invitrogen),  pC53SN3  for  wild-type  p53  (43), 
pRKETS2 (in which ETS2 is expressed from a CMV promoter, and which was provided by 
Eiji Hara, Paterson Institute), pSG5ERαHEGO (44), from which we generated the dominant 
negative ERα mutant S554fs by site directed mutagenesis, pERE-Tkluc contains 3 copies of Regulation of hdm2 in breast cancer    Phelps et al 
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the estrogen receptor binding element 5’ to a minimal promoter, and the mouse mdm2-P2 
promoter  reporter  vector,  mdm2luc  (30).  md2.9CAT0  (45)  was  used  to  generate  murine 
mdm2-P2 promoter sequence. For reporter assays, cells in 60 mm dishes were transfected 
using  Transfast  reagent  (Promega)  with  2  µg  reporter  plasmid,  0.25  µg 
pCDNA3.1mychislacZ and 0.05-1 µg of other expression vectors where indicated. Cells were 
assayed 44 h later using Luclite reagent and a Topcount plate reader (Packard Bioscience) for 
luciferase  reporter  gene  activity,  and  a  colorimetric  ß-galactosidase  assay  to  control  for 
transfection efficiency. Luciferase activity was normalised to ß-galactosidase and results are 
expressed  as  mean  relative  luciferase  units  (RLU).  Each  transfection  was  performed  in 
duplicate  and  results  are  presented  either  as  mean  RLU  +  SD  (n=2)  for  a  representative 
experiment or, where indicated, results were calculated as a percentage of the activity of the 
full length hdm2luc01 reporter vector in the cell line, and data from multiple experiments 
were pooled and expressed as mean + SEM. Statistical analysis was performed using a paired 
two-tailed t-test. 
 
RESULTS 
Expression of the hdm2-P2 promoter dependent mRNA is elevated in ERα
+ve breast 
cancer  cell  lines.  The  breast  cancer  cell  lines  for  this  study  were  selected  from  a  panel 
described in a previous report (23). MCF-7, ZR75.1, T47D and BT474 are ERα
+ve cell lines, 
whereas SKBr3 and MDAMB-231 are ERα
-ve. MCF-7 and ZR75.1 express wild-type p53 
protein  whereas  the  other  four  lines  express  p53  protein  containing  inactivating  point 
mutations  at  codons  194,  285,  175  and  280  in  T47D,  BT474,  SKBr3  and  MDAMB-231 
respectively. The study by Gudas et al (23) demonstrated that hdm2 protein levels, detected 
by western blotting with mAb IF2, were consistently higher in the ERα
+ve than ERα
-ve  cancer 
cell lines. Hdm2 protein is known to be highly phosphorylated at a number of sites that can Regulation of hdm2 in breast cancer    Phelps et al 
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affect  its  immunoreactivity  with  several  antibodies  (46),  and  therefore  we  first  sought  to 
confirm hdm2 expression levels in the breast cancer cell lines using a second mAb, 2A9 (42), 
the epitope for which (amino acids 155-222) is not known to be sensitive to post-translational 
modification. As shown in Fig. 1A (top panel), levels of the p90 form of hdm2 were highest 
in the 4 ERα
+ve cell lines, with MCF-7 cells having the lowest levels of this group, and 
ZR75.1  the  highest.  Hdm2  protein  levels  in  both  of  the  ERα
-ve  cell  lines  (SKBr3  and 
MDAMB-231) were determined, in two independent experiments, to be <10% of levels in 
ERα
+ve T47D cells, thus confirming the previous report (23). As shown in Fig. 1A, centre 
panel, in this panel of cell lines elevated levels of p53 protein correlate with the presence of 
an inactivating mutation in the p53 gene.  
To examine hdm2 mRNA expression levels in the breast cancer cell lines we used a 
RPA using an exon 2-exon 3 fragment of hdm2 cDNA as a probe (Fig. 1B). This probe is 
complementary to the 5’ region of the mRNA transcribed from the hdm2-P2 promoter (Fig. 
1B) and we were therefore able to quantitatively determine the levels of this transcript. The 
hdm2-P2 transcript was readily detectable in all of the ERα
+ve cell lines, whereas in the ERα
-
ve cell lines it was absent (MDAMB-231) or expressed at very low levels (levels in SKBr3 are 
<5% of those in MCF-7). The transcript from the hdm2-P1 promoter only partially protects 
the probe and therefore gives rise to a smaller fragment corresponding to part of exon 3 
(upper panel). This fragment was detected in all of the breast cancer cell lines at higher levels 
than the P2 transcript. Hdm2-P1 transcript expression was independent of ERα status, though 
P1 levels were 3-4 fold higher in T47D and BT474 cells than any of the other lines. It is 
theoretically possible that the exon 3 fragment is derived from mRNA other than the expected 
hdm2-P1 transcript, so semi-quantitative exon-specific RT-PCR was used to confirm hdm2 
transcript levels in the cell lines (Fig. 1B). The RT-PCR data for both the hdm2-P1 and -P2 
transcripts were comparable to that obtained with the RPA, with small differences in the Regulation of hdm2 in breast cancer    Phelps et al 
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relative levels of the P1 transcript being due to the semi-quantitative nature of the RT-PCR 
assay. 
These data demonstrate that hdm2 mRNA expression in breast cancer cells can be 
regulated  by  differential  expression  from  both  the  P1  and  P2  promoters.  It  is  known, 
however,  that  whilst  the  P1  mRNA  transcript  is  expressed  at  higher  levels  than  the  P2 
transcript in most cell types, it is translated approximately 8 fold less efficiently (34), and 
therefore  contributes  less  to  hdm2  protein  expression  levels.  Furthermore  we  found  that 
expression of the P2 transcript in the ERα
+ve breast cancer cells correlated with the elevated 
hdm2 protein levels in these cells, whereas the 3-4 fold increased levels of the P1 transcript in 
T47D and BT474 compared to MCF-7 and ZR75.1 were not associated with increased hdm2 
protein expression. We therefore proceeded to study in detail the mechanisms that regulate 
hdm2-P2 promoter activity in the breast cancer cell lines. 
Of the panel of cell lines we have used, MCF-7 and ZR75.1 are representative of the 
most common class of breast cancers, which both express ERα and retain wild-type p53. 
However it is not possible to study p53 independent hdm2-P2 promoter activity in these cells 
by  conventional  reporter  assays  as  the  transfection  procedure  induces  a  DNA  damage 
response,  and  consequent  activation  of  p53-responsive  promoters  such  as  hdm2-P2  (47). 
T47D  cells,  however,  express  inactive  mutant  p53  protein,  and  therefore  provide  a  good 
model to study p53 independent regulation of the hdm2-P2 promoter. To confirm that the 
mutant p53 in these cells cannot be activated by DNA damage, cells were exposed to 5 Gy γ-
irradiation  and  levels  of  hdm2-P2  transcript  determined  3  h  later.  Whilst  a  strong  p53 
dependent induction of hdm2-P2 transcripts occurred in MCF-7 cells, levels in T47D cells 
were unaffected by the radiation (data not shown). 
 Regulation of hdm2 in breast cancer    Phelps et al 
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Hdm2-P2 promoter activity is confined to ERα
+ve cell lines, but is independent of ERα 
function. Our first aim was to establish whether hdm2-P2 transcript levels correlate with ERα 
expression because the P2 promoter is dependent on ERα activity, or whether it may belong 
to  the  class  of  genes  that  are  estrogen  independent,  but  co-expressed  with  ERα  (5).  We 
therefore generated a luciferase reporter construct (hdm2luc01) containing 895 b.p. of DNA 
sequence flanking the hdm2-P2 promoter, including part of exon 1 through to sequence 3’ to 
the  start  ATG  in  exon  3  (Fig.  4A).  As  shown  in  Fig.  2Ai,  the  activity  of  this  promoter 
mirrored the cell-type specific expression of the P2 derived mRNA transcript, the reporter 
gene being efficiently expressed in ERα
+ve T47D cells, but not in the ERα
-ve SKBr3 line. To 
confirm that the reporter vector was able to function in SKBr3 cells if relevant activating 
transcription factors were present, we performed co-transfections with wild-type p53, which 
binds the tandem p53 response elements in the promoter, and demonstrated that the promoter 
was active in SKBr3 cells when wild-type p53 was expressed (Fig. 2Aii).  
This reporter vector was then used to determine the role of estrogen receptor function 
in driving hdm2-P2 promoter activity in T47D cells. The pure ERα antagonist ICI 182780 is 
able to effectively inhibit transcription from a bona fidae estrogen responsive promoter in 
T47D  cells  (Fig.  2B,  pERE-Tkluc),  whereas  we  demonstrate  that  it  has  no  effect  on 
expression from the hdm2luc01 vector (Fig. 2B). It is known, however, that in addition to its 
effect  on  promoters  containing  estrogen  response  elements,  ERα  is  also  able  to  enhance 
transcription through its ability to interact with, and increase the activity of, AP1 transcription 
factors, and this activity is not repressed by ERα antagonists (48). Indeed this function of 
ERα has previously been implicated in up-regulating mdm2 expression in transformed mouse 
fibroblasts (38). We therefore generated a dominant negative mutant of human ERα (ERα-
S554fs), which inhibits this activity of ERα and also down-regulates mdm2 expression in 
murine fibroblasts (38). ERα-S554fs had no effect on the activity of hdm2luc01 in T47D Regulation of hdm2 in breast cancer    Phelps et al 
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cells, despite blocking expression from the known ERα-responsive reporter in the same cells 
(Fig. 2C). Finally we demonstrate that forced over-expression of ERα in the ERα
-ve SKBr3 
cell line has no significant effect (P>0.05) on hdm2-P2 promoter activity, despite it being 
functionally active in the cells, as demonstrated by its ability to activate transcription from 
the bona fidae estrogen responsive reporter vector (Fig. 2D).  
 
Role  of  ras-raf-MEK-MAPK  signalling  in  regulating  hdm2-P2  promoter  activity  in 
T47D cells. Previous studies have identified a role for growth factor signalling through the 
ras-raf-MEK-MAPK cascade in the p53-independent regulation of mdm2/hdm2 expression 
(36, 37). The mechanism of raf-induced mdm2 expression has been dissected in the context 
of  the  murine  mdm2  promoter,  and  is  dependent  on  the  integrity  of  both  a  5’  ETS  site 
(ETSA), and a composite ras-response element (AP1-ETSB) (36). An alignment analysis of 
the hdm2 and mdm2 promoter regions (Fig. 3) showed that, whilst the AP1-ETSB element is 
conserved between species (labelled as AP1-ETSa in the human promoter), the ETSA site, 
which was demonstrated by Ries et al (36), to be necessary for raf-responsiveness, is not 
conserved.  Consistent  with  this  lack  of  conservation,  we  found  (data  not  shown)  that 
treatment of T47D cells with inhibitors of MEK (U0126 and PD98059) inhibited neither the 
expression  of  the  endogenous  hdm2-P2  transcript,  nor  transcription  from  the  hdm2luc01 
reporter vector. Expression from a murine mdm2 promoter vector was inhibited by U0126 in 
T47D cells. Consistent with the findings of Ries et al, however, we did find that U0126 
reduced levels of expression of hdm2 protein in human cancer cells, and we are currently 
examining the mechanism whereby this occurs. 
 
Dissection of transcription factor response elements responsible for hdm2-P2 promoter 
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are required for its activity in T47D  cells. Two approaches were undertaken: 1) deletion 
mapping  and  2)  inactivation  of  candidate  transcription  factor  binding  sites.  The  reporter 
vectors used in these studies are summarised in Fig. 4A.  
  Deletion mapping of the hdm2luc01 vector (Fig. 4B) determined that  55% of the total 
activity was lost when the 5’ region (-602 to –376) was deleted (compare hdm2luc01 with 
hdm2luc06,  P=0.006).  Deletion  of  the  region  -375  to  -133  resulted  in  a  smaller,  but 
significant reduction in activity (compare hdm2luc02 with hdm2luc03, P=0.001), whereas the 
reduction in activity observed by the deletion of sequences 3’ of +33 did not reach the level 
of statistical significance (compare hdm2luc06 with hdm2luc02, P=0.063). Therefore, whilst 
it is clear that multiple sequence elements are required for the full activity of the hdm2-P2 
promoter, at least one positive acting element is present between –602 and -376. A further 
deletion mutant (hdm2luc23) located this element to the sequence between –418 and –376 
(Fig. 4C, compare hdm2luc23 with hdm2luc06, P=0.006)). This 42 b.p. sequence consists 
almost  entirely  of  a  (nnGGGGC)5  repeat  sequence  (-416  to  -381).  A  potential  EBOX 
(CACGTG) is also present (-381 to -376), however destruction of this element by an internal 
3  b.p.  deletion  had  no  effect  on  promoter  activity  in  either  the  hdm2luc01  (Fig.  4C, 
hdm2luc01∆EBOX)  or  hdm2luc23  (not  shown)  backgrounds,  and  therefore  the  positive-
acting element is contained within the (nnGGGGC)5 repeat.  
The –375 to +293 region of the promoter (hdm2luc06 vector) retains 35-55% activity, 
and therefore we employed a candidate site approach to identify the positive acting elements 
in this region. Based on studies of the murine P2 promoter (36), three separate mutations 
were made in the hdm2luc01 vector, either singly or in combination, to inactivate potential 
transcription factor binding sites (Fig. 4A). The mutated sites were: 1) the conserved AP1 site 
(2 b.p. substitution), 2) the adjacent ETS response element (ETSB in mouse, ETSa in human, 
Fig. 3) (2 b.p. substitution), which together form an AP1-ETS ras response element in the Regulation of hdm2 in breast cancer    Phelps et al 
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murine promoter, and 3) the non-conserved (ETSb/c) sequence containing two potential ETS 
binding sites (10 b.p. deletion). As shown in Fig. 4D, deletion of the ETSb/c element had no 
effect on promoter activity in T47D cells, whereas mutation of the AP1 site resulted in a 
52.5% loss of promoter activity (hdm2luc01 vs hdm2luc01∆AP1, P<0.001), and the ETSa 
site  deletion  resulted  in  a  loss  of  29.6%  of  activity  (hdm2luc01  vs  hdm2luc01∆ETSa, 
P=0.003).  A  vector  containing  mutations  in  both  AP1  and  ETSa  elements  had  the  same 
activity as the AP1 site mutant (46.6% vs 47.5%).  
Having  determined  that  the  AP1-ETSa  site  in  the  hdm2-P2  promoter  confers 
approximately half of its p53-independent promoter activity in T47D cells, we were then able 
to determine to what extent transcriptional activation through this element contributes to the 
level  of  hdm2-P2  promoter  activity  in  the  MCF-7  cell  line  (Fig.  4D).  Whilst  overall 
hdm2luc01 activity was approximately 40 fold higher in MCF-7 cells than T47D (in Fig. 4D, 
promoter activity is presented as a percentage of hdm2luc01 activity in each cell line), due in 
part to the activation of p53 by the transfection process (data not shown), inactivation of the 
AP1-ETSa element also reduced promoter activity to approximately 50% in MCF-7 cells.  
 
ETS2 over-expression reconstitutes hdm2-P2 promoter activity in SKBr3 cells through 
the  same  elements  that  drive  constitutive  hdm2-P2  expression  in  T47D  cells.  Having 
identified the cis-acting elements necessary for hdm2-P2 promoter activity in ERα
+ve T47D 
and MCF-7 cells, we then wished to determine why the promoter is inactive in the ERα
-ve cell 
lines. Expression from the murine P2 promoter is known to be dependent on the levels of 
transcriptional activation through the AP1-ETS element and its activity can be induced by the 
transient over-expression of AP1 or ETS transcription factors (36). We therefore transfected 
SKBr3 cells with an expression vector encoding ETS2 in order to determine whether the lack 
of hdm2-P2 transcription in these cells is due to limiting activity of the AP1-ETS binding Regulation of hdm2 in breast cancer    Phelps et al 
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transcription factors. ETS2 is known to be able to activate transcription of the murine mdm2-
P2 promoter when over-expressed in fibroblasts (36) and is normally expressed in all of the 
breast cancer cell lines used in this study at similar levels (Fig. 5A) (49). Transfection of 
SKBr3  cells  with  the  ETS2  expression  vector  resulted  in  an  elevation  in  ETS2  protein 
expression levels (Fig. 5A), and a significant (P=0.007) 5-fold activation of the hdm2luc01 
reporter vector (Fig. 5B). ETS2 also activated the hdm2luc01 reporter vector in the other 
ERα
-ve cell line, MDAMB-231 (not shown). Hdm2-P2 activation by ETS2 in SKBr3 cells 
was dependent of the integrity of the AP1-ETS element in the promoter as there was no 
significant activation of hdm2luc01∆AP1ETSa by ETS2 (P=0.073) (Fig. 5B).  Consistent 
with the requirements for basal hdm2-P2 promoter activity in T47D cells, effective ETS2 
activation  of  the  promoter  in  SKBr3  cells  was  also  dependent  on  the  GC-rich  repeat 
sequences present in hdm2luc01, and -23, but not -06 reporter vectors (Fig. 5B).  
  Finally we wished to confirm that ETS2 over-expression in ERα
-ve cells was capable 
of  inducing  the  expression  of  functional  hdm2  protein.  SKBr3  cells  were  therefore 
transfected with increasing amounts (0-1 µg) of pRKETS2 plasmid, and levels of endogenous 
hdm2 and p53 proteins determined by western blotting (Fig. 5C). ETS2 transfection resulted 
in a clear increase in hdm2 protein levels, and a concomitant decrease in the levels of mutant 
p53 protein, consistent with increased rates of hdm2 dependent degradation of p53 by the 
proteosome. 
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DISCUSSION   
  In this study we have confirmed previous findings (23) that elevated levels of hdm2 
protein expression correlate with ERα
+ve status in a panel of 6 breast cancer cell lines. We 
have therefore used these cell lines to investigate the mechanisms whereby hdm2 expression 
is regulated in breast cancer cells. We firstly determined that high hdm2 protein expression 
correlated with increased levels of transcription from the hdm2-P2 promoter, and identified 
T47D as a cell line in which the p53 inducible hdm2-P2 promoter is constitutively active, 
despite p53 being expressed in a functionally compromised, mutant form in the cells. We 
show that this activity is dependent on at least three different predicted transcription factor 
binding sites: an AP1 site, an ETS site, which together form a bi-partite AP1-ETS element at 
-120 to -99, and  a series of 5 consecutive nnGGGGC repeats at –415  to –381. We also 
demonstrate that transcriptional activation by the AP1-ETS element drives expression of the 
hdm2-P2 promoter in the ERα
+ve cell line, MCF-7. These cells express wild-type, functional 
p53 protein and are widely used as a model system that is representative of the majority of 
human breast cancers, which are both ERα
+ve and p53 wild-type.  
  In contrast, however, the hdm2-P2 transcript was not efficiently expressed in the ERα
-
ve cell lines SKBr3 or MDAMB-231. Several lines of evidence demonstrate that this lack of 
expression is due to a loss of transcriptional activation through the AP1-ETS element in these 
cell lines: 1) in contrast to results from T47D cells, mutation of the AP1-ETS element has no 
effect on the low basal activity of the hdm2-P2 promoter in SKBr3 cells, demonstrating that 
there  is  no  activation  of  transcription  through  this  element  in  SKBr3  2)  removal  of  the 
nnGGGGC repeats does result in a loss of the residual promoter activity in SKBr3 cells (Fig. 
5B, hdm2luc23 vs hdm2luc06), demonstrating that the mechanism whereby promoter activity 
is stimulated through these repeats is functional in SKBr3, and 3) the over-expression of an 
ETS factor, ETS2, is able to reconstitute hdm2-P2 promoter activity in SKBr3 cells in an Regulation of hdm2 in breast cancer    Phelps et al 
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AP1-ETS element dependent manner. As was found to be the case for the constitutive hdm2-
P2 promoter activity in T47D cells, maximal ETS2 induced P2 activity in SKBr3 cells was 
dependent on the integrity of both the AP1-ETS and nnGGGGC repeat sequence. The precise 
mechanism  whereby  this  nnGGGGC  element  contributes  to  transcription  remains  to  be 
elucidated. Whilst there is no clearly identifiable transcription factor-binding element in the 
sequence, it bears similarity to the consensus for factors such as SP1, which binds a direct 
repeat  of  GGGGC  without  a  spacer  (50).  Both  SV40  LT  and  PyLT  viral  proteins  direct 
transcription through GGGGC direct repeats similar to the one in the hdm2-P2 promoter, and 
can  inhibit  the  expression  of  cellular  genes  by  displacing  factors,  such  as  the  recently 
identified Rnf6, from such elements (51). 
Whilst over-expression of ETS2 is able to reconstitute hdm2-P2 promoter activity in 
SKBr3 cells, we show that the lack of P2 activity in these cells is unlikely to be simply as 
consequence of lack of ETS2 protein expression, as ETS2 is expressed at similar levels in all 
the breast cancer cell lines examined. Activation of transcription through composite AP1-
ETS elements normally involves the co-operative activation by both AP1 and ETS family 
members. Not only are these families comprised of multiple members with differing activities 
(over 20 in the case of ETS) (52), many of which can form hetero-dimers with other family 
members, but both protein families are subject to control by post-translational modification, 
and the interaction with both positive and negative regulatory  factors (53-55) . We have 
considered  pathways  which  have  been  previously  shown  to  regulate  mdm2-P2  promoter 
activity to determine whether they may account for the activity of the AP1-ETS element in 
the hdm2-P2 promoter in ERα
+ve, but not ERα
-ve cells. However, the activity in ERα
+ve cells is 
neither due to the stimulation of AP1 factors by interaction with ERα (38), or the activation 
of AP1 or ETS factors by ras-raf-MEK-signalling (36). Additionally, using electrophoretic 
mobility shift analysis with the AP1-ETS sequence as a probe, we detect specific binding Regulation of hdm2 in breast cancer    Phelps et al 
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complexes of similar mobilities in the nuclear lysates of both T47D and SKBr3 cells (data not 
shown). The expression of a large number of genes are known to be differentially regulated 
between ERα
+ve and ERα
-ve breast tumors (6), and both AP1 (data not shown) (56) and ETS 
factor (57) expression shows considerable variation between different breast cancer  cells. 
Based on our cell line study and a recent analysis of breast tumor samples (27), the hdm2-P2 
promoter may be included in the group of genes whose expression is co-ordinately regulated 
with ERα in breast cancers. 
  During the course of our investigations, we have also identified striking differences 
between human and murine hdm2/mdm2 in the ability of the ras-raf-MEK-MAPK signalling 
cascade to regulate P2 promoter activity. This finding is critical to our understanding of how 
hdm2  expression  is  regulated  in  a  wide  range  of  normal  and  malignant  human  cells. 
Specifically, whilst mdm2 mRNA and protein expression can be induced by this signalling 
pathway in murine fibroblasts (36), and in human cancer cells both hdm2 protein expression 
and  transcription  from  the  murine  mdm2-P2  promoter  reporter  vector,  are  sensitive  to 
inhibition of MEK activity, transcription from the human hdm2-P2 promoter is not MEK 
dependent in the human cancer cell lines. This species-specific difference can be explained 
by a lack of conservation of the transcription factor binding site in the two promoters, as a 
single ETS factor binding site (ETSA) that is required for ras-raf- MEK-MAPK induction of 
the murine promoter (36) is not present in the human, and instead constitutive activity of the 
human promoter in T47D cells is dependent on the nnGGGGCC repeat element. Ras-raf-
MEK-MAPK signalling must therefore utilise an hdm2-P2 promoter independent mechanism 
to  regulate  hdm2  protein  levels  in  human  cells,  as  has  recently  been  described  for  the 
inhibition of hdm2 expression by hypoxia (58). 
Our  study  has  a  number  of  important  implications  regarding  how  levels  of  p53 
activity  may  be  regulated  during  the  development  of  breast,  and  most  probably  other, Regulation of hdm2 in breast cancer    Phelps et al 
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malignancies. Firstly, inactivation of p53 by its exclusion from the nucleus, which occurs in 
approximately 30% of breast cancers and also in normal breast tissue (15), is known to be 
dependent  on  the  expression  of  hdm2  (59)  and  it  is  therefore  probable  that  the  p53-
independent transcription of hdm2 we have described will promote the nuclear exclusion of 
wild-type  p53  in  ERα
+ve  breast  cancer  cells.  Secondly,  the  widely  reported  correlation 
between the presence of inactivating mutations of p53, and elevated p53 protein levels, is a 
consequence of the inactive p53 mutant protein no longer driving the expression of the hdm2 
protein required to target their own degradation (60, 61). The loss of this correlation which is 
observed in significant numbers of breast cancers (8, 9) is likely to be due in part to p53-
independent expression of hdm2 in a proportion of these tumors.  
Finally,  our  demonstration  that  the  elevated  levels  of  hdm2  expression  in  ERα
+ve 
breast cancer cells are not merely a consequence of transcriptional activation by wild-type 
p53,  confirms  the  presence  of  a  p53-independent  mechanism  whereby  the  p53-hdm2 
negative-regulatory feedback loop is modified in these cells to reduce levels of cellular p53 
activity. These data clearly strengthen the previously un-investigated hypothesis (14) that 
differences between cancer cells, such as cell-lineage- or differentiation- dependent activity 
of  transcription  factors  like  AP1  or  ETS,  may  determine  the  frequency  at  which  p53-
mutations are observed in individual tumor types, through the regulation of hdm2 expression 
levels. 
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FIGURE LEGENDS 
 
Fig. 1. Hdm2 protein and mRNA transcript levels in a panel of breast cancer cell lines. 
(A) Whole cell protein lysates were analysed by western blotting and probed with antibodies 
mAb 2A9 for hdm2 and DO-1 for p53. MCF-7, ZR75.1, T47D and BT474 are ERα
+ve cell 
lines,  SKBr3  and  MDAMB-231  are  ERα
-ve.  (B)  Levels  of  hdm2-P1  and  -P2  mRNA 
transcripts were determined by quantitative RPA (upper panels) using an hdm2 exon2-exon3 
probe (see diagram). Protected fragment sizes are 128 b.p. for the P2 transcript (containing 
exons 2 and 3), and 81 b.p. for the P1 transcript, which only protects the exon 3 portion of the 
probe. The ladders below the main bands are due to ‘breathing’ of the ends of the probes. A 
GAPDH probe was used to control for input  mRNA levels. Results from the RPA were 
confirmed using exon-specific RT-PCR (lower panels) using O1b/O3 and O2/O3 primer pairs 
for the P1 and P2 promoter transcript respectively (see diagram). β actin primers were used to 
control for input mRNA levels. All PCR reactions were initially optimised to ensure that they 
were stopped in the exponential phase (not shown). 
 
Fig. 2. Role of ERα in regulating hdm2-P2 promoter activity. (A) ERα
+ve T47D (solid 
bars) and ERα
-ve SKBr3 (open bars) cells were transfected with 2 µg of either pGL3-basic or 
the hdm2-P2 reporter vector hdm2luc01. (Ai) Reporter vector only; (Aii) reporter vector plus 
50 ng wild-type p53 expression vector pC53SN3. (B) T47D cells were transfected with either 
hdm2luc01 or the pERE-Tkluc reporter plasmid. Cells were then cultured for 40 h before 
assay in the presence of either DMSO control (open bars) or 20 nM of the ERα antagonist ICI 
182780 (solid bars). (C) T47D cells were transfected with either hdm2luc01 or pERE-Tkluc 
in the presence of 1 µg of either pcDNA3.1 control vector (open bars) or dominant negative 
ERα (ERα-S554fs) expression vector (solid bars). (D) SKBr3 cells were transfected with 
either hdm2luc01 or pERE-Tkluc in the presence (solid bars) or absence (open bars) of 0.2 µg Regulation of hdm2 in breast cancer    Phelps et al 
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ERα expression vector, pSG5ERαHEGO. (A-D) Each experiment was repeated at least twice, 
and  data  from  a  representative  experiment  is  shown.  Data  are  mean  +  SD  for  duplicate 
assays. 
 
 
Fig. 3. Alignment of human and mouse hdm2/mdm2-P2 promoter region. Human intron 1 
sequence  was  obtained  from  the  human  genome  database  (AC026121.10).  Mouse  P2 
promoter  sequence  was  compiled  from  published  promoter  sequence  (45)  as  well  as 
sequencing of the plasmid md2.9CAT0 for the region 5’ to the start of the mdm2luc plasmid. 
Alignment was performed using MacVector and homologous regions are shaded. The upper 
row is the mouse sequence. The 5’ ends of the hdm2luc reporter vectors described in Fig. 4A 
are indicated, with the exception of hdm2luc01 which also encompasses part of exon 1, and 
luc02, which starts at the same position as luc06. Potential transcription-factor binding sites 
indicated were identified using MatInspector, using a cut-off of 0.95/0.95 for core and matrix 
fits. Additional sites shown are the p53 response elements (P53 RE) 1 and 2, mouse ETSB 
(36)and the homologous human ETSa site (both with a matrix fit of <0.9), and the potential 
human ETSb/c sites (matrix fit 0.92).    
 
Fig. 4. Dissection of hdm2-P2 promoter response elements. 
(A) Hdm2-P2 promoter  map and reporter vectors. Boxes  I-III  represent  hdm2 exons 1-3. 
Numbering is relative to the start of exon 2. Solid boxes indicate the p53 response elements. 
The  deletion  series  of  hdm2  reporter  vectors  is  shown  relative  to  the  full  construct 
hdm2luc01. Potential transcription factor response elements where mutations were introduced 
are indicated. The sequence of the 42 b.p. region at the 5’ end of luc23 (difference between 
luc06  and  luc23)  contains  5  GC-rich  repeats  adjacent  to  an  EBOX  site  (underlined)  as Regulation of hdm2 in breast cancer    Phelps et al 
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follows:    GC(TGGGGGC)(TCGGGGC)(GCGGGGC)(GCGGGGC)(ATGGGGC)ACGTG. 
The (nnGGGGC)5 repeats are represented by a solid triangle on the diagram. (B) T47D cells 
were transfected with hdm2luc01 reporter construct and the hdm2luc06, 02 and 03 deletion 
constructs as indicated. Results are expressed as a percentage of hdm2luc01 activity (mean + 
SEM), with data pooled from 5 independent experiments. (C) T47D cells were transfected 
with the reporter constructs indicated. (D) T47D (solid bars) cells were transfected with the 
constructs indicated. Open bars represent the results from a separate experiment in which 
MCF-7 cells were transfected with hdm2luc01 or hdm2luc01∆AP1-ETSa reporter vectors. 
Note that the activity of hdm2luc01 in MCF-7 cells was approximately 40 fold higher than in 
T47D due to the activity of wild-type p53. Data in (C) and (D) are pooled from two or more 
independent experiments (C, n=4; D, n=6) and expressed as in (B). 
 
Fig. 5. Reconstitution of hdm2-P2 promoter activity in SKBr3 cells. (A) Left panel; levels 
of ETS2 protein in the six breast cancer cell lines were determined by western blotting. Right 
panel; SKBr3 cells were transfected with 2 µg carrier DNA (hdm2luc01 plasmid) plus either 
0 or 100 ng of pRKETS2 expression vector as indicated. 48 h after transfection cells were 
lysed and analysed for ETS2 protein expression by western blotting. (B) SKBr3 cells were 
transfected with the reporter constructs indicated, either with (solid bars) or without (open 
bars)  100  ng  pRKETS2  over-expression  vector.  Data  are  derived  from  two  independent 
experiments, (n=4). (C) SKBr3 cells were transfected with 0–1 µg pRKETS2 as indicated. 
Total plasmid transfected was made up to 1 µg with pcDNA3.1. Whole cell lysates were 
prepared after 36 h. Western blots were probed with antibodies mAb 2A10 for hdm2 and DO-
12 for p53.  Regulation of hdm2 in breast cancer    Phelps et al 
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Fig. 4 
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